Sun, Feb 1, 2015, 7:58 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Santarus, Inc. (SNTS) Message Board

  • salseroomega salseroomega Oct 10, 2013 10:30 PM Flag

    3rd quarter will beat estimates.

    The price increases for Glumetza 8%, and Zegerid 10%, started in June 2013. therefore those price increases will impact the 3rd and 4th Quarters. The last two Quarters Glumetza and Zegerid contributed approximately $66M. If we increase that same amount by the respective price increases we get Glumetza $45.7M plus Zegerid $25M = $70.7M. Cycloset and Fenoglide I don't expect much from probably $6.3M, other revenue will probably remain the same $0.9M. I believe Uceris will produce $20M - $21M. Therefore, there will be a total of $97.9M - $98.9M for the quarter.

    Uceris numbers are July 982, 1,097, 1,038, 1138 = 4,255

    August 1,196, 1,084, 1,150 (approximate), 1,196 + Aug 30 = 4,626 plus one week and one day
8,881 plus 5 weeks and a few days. Therefore, to reach 14,234 scripts needed for $20M
14,234 - 8,881= 5,353 in 5 weeks and a few days = average scripts per week needed would be less than 1,071. The last 5 weeks they've beaten this average number, I don't think this will be a problem, IMO.

    Therefore, the 3rd quarter (which was a slow quarter) will beat estimates. SNTS investors will have much to celebrate very soon.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
31.960.00(0.00%)Dec 31 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.